Jupiter Endovascular Secures Over $40M in Series B Funding for Innovative Catheter Platform

Jupiter Endovascular, a startup spun out of Neptune Medical last year, has successfully raised more than its targeted $40 million in a Series B funding round. The company plans to utilize these funds to further develop and launch its groundbreaking TFX catheter platform, which is part of the Vertex system.

FDA Clearance and First-in-Human Trial Results

The U.S. Food and Drug Administration (FDA) granted 510(k) clearance to the Vertex Catheter system incorporating the TFX platform in September. This clearance allows Jupiter Endovascular to legally market the medium-risk device in the United States. The company is set to present the results of its first-in-human trial of the system at the upcoming Transcatheter Cardiovascular Therapeutics Conference in San Francisco.

Addressing Unmet Needs in Transcatheter Interventions

The TFX platform is designed to enable practitioners to treat areas in the human body that are not safely or easily reached using conventional endovascular systems. Carl St. Bernard, Jupiter's chief executive, emphasized the significance of this development, stating, "We're energized by the support of this distinguished syndicate of investors as we tackle one of the greatest unmet needs in transcatheter interventions—the lack of stability and control physicians face while operating in complex cardiovascular anatomies—starting with pulmonary embolism."

Investment Details and Company Background

While the exact amount raised was not disclosed, the Series B funding round exceeded the initial $40 million target. The round was led by Sonder Capital, with participation from Senvest Management, LB Investment, and an unnamed corporate investor. Jupiter Endovascular was formed in August 2024 with $21 million in seed funding, which came from a $97 million Series D venture capital round raised by its parent company, Neptune Medical. The startup's primary focus is on improving the precision and control of catheter-based therapies, with an initial emphasis on treating blood clots lodged within the lung.